HIV molecular immunology database

 

Search CTL/CD8+ T-Cell Epitope Database

Found 2 matching records:

Displaying record number 885

Download this epitope record as JSON.

HXB2 Location gp160(828-836)
gp41(317-325)
DNA(8706..8732)
gp160 Epitope Map
Author Location Env(829-837 subtype B)
Epitope RVIEVLQRA Epitope Alignment
RVIEVLQRA epitope logo
Subtype B
Species (MHC/HLA) human(A*02:01)
Immunogen vaccine
Experimental methods  
Keywords binding affinity

Vaccine Details

Vaccine type protein
Vaccine strain B clade MN
Vaccine component gp160

Notes

References

Kundu1998a S. K. Kundu, M. Dupuis, A. Sette, E. Celis, F. Dorner, M. Eibl, and T. C. Merigan. Role of preimmunization virus sequences in cellular immunity in HIV- infected patients during HIV type 1 MN recombinant gp160 immunization. AIDS Res. Hum. Retroviruses, 14:1669-78, 1998. PubMed ID: 9870321. Show all entries for this paper.


Displaying record number 58644

Download this epitope record as JSON.

HXB2 Location gp160(828-836)
gp41(317-325)
DNA(8706..8732)
gp160 Epitope Map
Author Location Env(829-837 LAI)
Epitope RVIEVLQRA Epitope Alignment
RVIEVLQRA epitope logo
Epitope Name Env829-837
Subtype B
Species (MHC/HLA) human(A*02:01)
Immunogen vaccine
Country United States
Experimental methods Chromium-release assay
Keywords dendritic cells, enhancing activity

Vaccine Details

Vaccine type protein
Vaccine strain B clade MN
Vaccine component gp160

Notes

References

Dupuis1995 M. Dupuis, S. K. Kundu, and T. C. Merigan. Characterization of HLA-A*0201-Restricted Cytotoxic T Cell Epitopes in Conserved Regions of the HIV Type 1 gp160 Protein. J. Immunol., 155:2232-2239, 1995. Five HLA-A2 HIV-1 seropositive HIV-1 MN rec gp160 vaccinees had their CTL activity assessed using peptides known to bind with high affinity to HLA-A*0201. Four of the patients had specific CTL activity for a minimum of at least three epitopes, thus the response appears heterogeneous. One of the four peptides was confirmed to be HLA A2 restricted. Epitopes were highly conserved. PubMed ID: 7543542. Show all entries for this paper.


Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health